Table 2.
Treatment duration and best response of SD or PR in non-TGCT patients.
| Tumor | Total treatment duration (days) | Best response |
|---|---|---|
| GIST | 80 | SD |
| GIST | 111 | SD |
| GIST | 169 | SD |
| GIST | 345 | SD |
| MEC | 350 | SD |
| Malignant effusiona | 55 | SD |
| Malignant effusionb | 263 | SD |
| Malignant effusionc | 56 | SD |
| Familial schwannomatosis | 187 | SD |
| Neurofibromatosis | 199 | SD |
| Neurofibromatosis | 113 | SD |
| ACC | 57 | SD |
| Mesothelioma | 150 | SD |
| Pancreatic neuroendocrine tumor | 413 | SD |
| Erdheim–Chester disease | 494 | PR |
| Mesothelioma | 55 | SD |
Abbreviations: ACC, adenoid cystic carcinoma; GIST, gastrointestinal stromal tumor; MEC, mucoepidermal carcinoma; SD, stable disease; PR, partial response; TGCT, tenosynovial giant cell tumor.
aNon–small cell lung cancer.
bMesothelioma.
cColon cancer.